

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司 SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT FLUCONAZOLE TABLETS PASS CONSISTENCY EVALUATION

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the National Medical Products Administration has approved the passing of the Consistency of Quality and Efficacy Evaluation for Generic Drugs for Fluconazole Tablets (brand name “依利康”) (150mg and 50mg) of Shijiazhuang No. 4 Pharmaceutical Co., Ltd., a subsidiary of the Company.

Fluconazole is a broad-spectrum antifungal drug mainly used for the treatment and prevention of various fungal infections, including cryptococcal meningitis, coccidioidomycosis, invasive candidiasis and mucosal candidiasis.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board
Chow Hing Yeung
Company Secretary

Hong Kong, 17 May 2019

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Wang Xianjun and Mr. Su Xuejun as executive Directors, Mr. Feng Hao as non-executive Director and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.